Neuropathic pain conditions including neuropathic orofacial pain (NOP) are difficult to treat.
Contemporary therapeutic agents for neuropathic pain are often ineffective in relieving pain …

A great need exists for the development of new medications to treat pain resulting from
various disease states and types of injury. Given that the endogenous cannabinoid (that is …

Synthetic and naturally occurring cannabinoids are a focus of strong social, legal, and
medical controversy concerning their therapeutic utility, yet studies show that cannabinoids …

Direct-acting cannabinoid receptor agonists are well known to reduce hyperalgesic
responses and allodynia after nerve injury, although their psychoactive side effects have …

Neuropathic orofacial pain (NOP) exists in several forms including pathologies such as
burning mouth syndrome (BMS), persistent idiopathic facial pain (PIFP), trigeminal neuralgia …

Chronic neuropathic pain is a debilitating condition that remains poorly treated by current
medications. Preclinical studies have indicated that cannabinoid receptor agonists have …

The research of new therapeutic strategies for neuropathic pain represents a major current
priority. Important drawbacks to advance in the development of these therapies are the …

The cannabinoid receptors CB1 and CB2 are class A G-protein-coupled receptors. It is well
known that cannabinoid receptor agonists produce relief of pain in a variety of animal …

Despite the importance of pain as a warning physiological system, chronic neuropathic pain
is frequently caused by damage in the nervous system, followed by persistence over a long …

The endocannabinoids anandamide and 2-arachidonoylglycerol are predominantly
regulated by the respective catabolic enzymes fatty acid amide hydrolase (FAAH) and …